What is the official ID of this bill?

The official print number for this legislation is HR 2883.

When did the legislative process begin?

The process officially started on 2021-04-28.

Where can I read the full text of this legislation?

The full official text is available at: https://www.congress.gov/117/bills/hr2883/BILLS-117hr2883ih.htm

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

Who is the primary sponsor?

The primary sponsor is Rep. Jeffries, Hakeem S. [D-NY-8].

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

What is the latest detailed status?

The latest detailed status is: Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 31 - 9.

Analysis and Potential Impact of HR 2883

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

Faster Access to Affordable Medicines: Stopping Competition Blockades

Q: What are the main provisions?

Key points include: Facilitates access to more affordable generic and biosimilar drugs, potentially lowering healthcare costs for citizens. Imposes financial penalties on companies that intentionally delay the approval of cheaper drug alternatives. Strengthens the Federal Trade Commission's role in combating unfair market practices in the pharmaceutical industry.

This bill aims to speed up the market entry of cheaper generic and biosimilar drugs. It prevents pharmaceutical companies from blocking competition by filing baseless petitions, which should lower drug prices and increase their availability for citizens.

Key points

Facilitates access to more affordable generic and biosimilar drugs, potentially lowering healthcare costs for citizens.

Imposes financial penalties on companies that intentionally delay the approval of cheaper drug alternatives.

Strengthens the Federal Trade Commission's role in combating unfair market practices in the pharmaceutical industry.

article Official text account_balance Process page notifications_active Track this Bill

gavel

Status:

Expired

Record your position for audit.

Why does your vote on bills matter?

It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.

Additional Information

Stop Stalling Access to Affordable Medications

Print number: HR 2883

Sponsor: Rep. Jeffries, Hakeem S. [D-NY-8]

Process start date: 2021-04-28

System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.

Summarized by: gemini-2.5-flash-preview-05-20

Source data: api.congress.gov

AI work logs for this document launch

Faster Access to Affordable Medicines: Stopping Competition Blockades

Key Questions about Faster Access to Affordable Medicines: Stopping Competition Blockades